Tagged with M

USA Stephen J. Ubl, president and CEO of PhRMA, outlines the unprecedented collaboration and speed with which the biopharmaceutical industry has responded to the COVID-19 pandemic and the solutions that PhRMA is proposing to lower patient costs while protecting innovation and access.   We know that our innovation and our collaboration…

Turkey When Abdi Ibrahim acquired a 28.5 percent stake in Swiss biotech OM Pharma in September 2020, it represented a historic moment for Turkey’s pharma industry; the first time a Turkish firm had ever taken part in the management of a European company.   With this partnership agreement, the long trend…

Mexico COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian generics firms to establish a pharma hub for manufacturing and logistics.   One of the leading pharma markets in Latin…

Global Merck Healthcare’s newly appointed Global Head of Business innovation, Renée C. Amundsen, highlights the numerous opportunities for change management that the COVID-19 pandemic has thrown up, why company-HCP interaction might never be the same again, and shares some pearls of wisdom for other women in pharma.   I see Merck’s…

Talent COVID-19 has necessitated enormous shifts in the way we live, work, and communicate with each other. Nowhere is this more apparent professionally than for those starting a new job. Here, we highlight four recent appointees to new roles in pharma companies across Europe and the USA and how they have…

Switzerland In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great place to work.   I was told when I came that Switzerland is a safe haven with easy access. What…

USA Brad Campbell, president and COO of US rare disease specialist Amicus, talks domestic and global product launches, the company’s first steps into the gene therapy space, and how a biotech success story like Amicus can be a guiding light in market access and pricing discussions. Ultimately, we envision our competition…

Switzerland Alfasigma Switzerland’s Dr Tytus Litynski introduces the Italian firm’s diversified portfolio of both Rx drugs and food supplements in Switzerland, why internal innovation remains the company’s core focus, and how stakeholder relations have had to evolve in the COVID-19 era.   One advantage of being a family-owned rather than a…

China Following a recent capital injection of USD 67 million, Chinese biotech EdiGene is set to advance its pipeline in gene editing treatments and therapies as it becomes a clinical-phase company. The company’s CEO spoke to PharmaBoardroom about how Edigene’s technology platforms differ from those of other firms, and why the…

Brazil Six of the top ten companies in the Brazilian pharma market are domestic.* Read on for an introduction to some of the Brazilian giants that are perhaps less well known internationally but play a leading role in what is the world’s sixth largest pharma market, serving a patient population of…

Roundup The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing struggle with COVID-19; issues around unchecked use of an anti-parasite drug; and the seismic economic and social impact of upcoming cannabis legalisation in Mexico.   Six Indian drug…

USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture.   This is a very exciting moment…